Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T36832 |
PDE4B-IN-2
A 33 |
PDE | Metabolism |
PDE4B-IN-2 (A 33) 是一种具有口服活性,选择性 PDE4B 抑制剂,IC50 为 15 nM。PDE4B-IN-2 抑制 PDE4D (IC50=1.7 µM)。PDE4B-IN-2 表现出有效的抗炎作用。 | |||
T62064 | PDE4B/7A-IN-2 | ||
5-HT1A/5-HT7受体拮抗剂(5-HT1A Ki=8 nM,Kb=0.04 nM;5-HT7 Ki=451 nM,Kb=460 nM)具有 PDE4B/PDE7A 抑制活性(PDE4BIC50=80.4μM;PDE7AIC50=151.3μM),其抗抑郁样作用强于作为参考活性分子的依西酞普兰。 | |||
T72031 |
BI 1015550
|
PDE | Metabolism |
BI 1015550 是一种具有口服活性的PDE4B 抑制剂,IC50值为 7.2 nM。BI 1015550 具有良好的安全性,在炎症、过敏疾病、肺纤维化和慢性阻塞性肺疾病 (COPD) 中有潜在应用。 | |||
T38002 | LEO 39652 | ||
LEO 39652 is a dual-soft PDE4 inhibitor with IC50s of 1.2 nM, 1.2 nM, 3.0 nM and 3.8 nM for PDE4A, PDE4B, PDE4C and PDE4D, respectively. LEO 39652 also inhibits TNF-α with an IC50 value of 6.0 nM. LEO 39652 is used for topical research of Atopic dermatitis (AD) [1]. LEO 39652 shows unbound in vitro potency when measured as LPS induced TNF-α release in human peripheral blood mononuclear cells (PBMC), incubated in serum free medium. LEO 39652 shows a relatively high binding to human serum albumin... |